← Back to headlines
Truist Lowers BeOne Medicines Price Target to $411
Truist has adjusted its price target for BeOne Medicines, lowering it to $411 from $412. This change indicates a revised valuation perspective for the pharmaceutical company.
9 Apr, 12:41 — 9 Apr, 12:41
Sources
Showing 1 of 1 sources
